This video was originally broadcasted on 7 July 2020
Speaker: Richard Holt
This promotional webinar series and respective materials have been developed, organised and funded by Novo Nordisk. For healthcare professionals only.
Click here to view prescribing information and adverse event reporting information for insulin degludec (Tresiba®). Insulin degludec (Tresiba®) is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year.
Date of prep: December 2020 – Job code: UK20TSM00258
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcardor search for MHRA Yellow Card in the Google Play or Apple App Store.Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be
monitored for training purposes.